Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage company focused on developing therapies for neurodegenerative disorders, announced its financial results for the year ended December 31, 2025. The company reported a net loss of $23.5 million, or $(0.32) per share, compared to a net loss of $34.0 million, or $(0.86) per share for 2024. The decrease in net loss reflects reduced research and development expenses, which were $37.2 million for 2025, down from $41.7 million in the previous year. Cognition Therapeutics highlighted its cash position of approximately $37 million as of December 31, 2025, which is expected to fund operations through the second quarter of 2027.

The company is advancing its lead product candidate, zervimesine (CT1812), which is currently in clinical trials for dementia with Lewy bodies (DLB) and Alzheimer’s disease. The company has received positive feedback from regulators regarding its clinical development plans, particularly for DLB psychosis, where no approved treatment options currently exist. Cognition plans to meet with the FDA's Division of Psychiatry by mid-2026 to discuss its registrational plan for zervimesine.

Cognition Therapeutics also reported that its 'START' trial in early Alzheimer’s disease has completed enrollment, with topline results expected in 2027. The company’s clinical and operational highlights include published results from the Phase 2 'SHIMMER' study in DLB, which demonstrated strong therapeutic responses across various behavioral domains, particularly in psychosis. The company is optimistic about the potential of zervimesine to address significant unmet needs in neurodegenerative diseases, particularly given the lack of approved therapies for DLB psychosis.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.